Literature DB >> 17641018

Steady state dendritic cells present parenchymal self-antigen and contribute to, but are not essential for, tolerization of naive and Th1 effector CD4 cells.

Adam T Hagymasi1, Aaron M Slaiby, Marianne A Mihalyo, Harry Z Qui, David J Zammit, Leo Lefrancois, Adam J Adler.   

Abstract

Bone marrow-derived APC are critical for both priming effector/memory T cell responses to pathogens and inducing peripheral tolerance in self-reactive T cells. In particular, dendritic cells (DC) can acquire peripheral self-Ags under steady state conditions and are thought to present them to cognate T cells in a default tolerogenic manner, whereas exposure to pathogen-associated inflammatory mediators during the acquisition of pathogen-derived Ags appears to reprogram DCs to prime effector and memory T cell function. Recent studies have confirmed the critical role of DCs in priming CD8 cell effector responses to certain pathogens, although the necessity of steady state DCs in programming T cell tolerance to peripheral self-Ags has not been directly tested. In the current study, the role of steady state DCs in programming self-reactive CD4 cell peripheral tolerance was assessed by combining the CD11c-diphtheria toxin receptor transgenic system, in which DC can be depleted via treatment with diphtheria toxin, with a TCR-transgenic adoptive transfer system in which either naive or Th1 effector CD4 cells are induced to undergo tolerization after exposure to cognate parenchymally derived self-Ag. Although steady state DCs present parenchymal self-Ag and contribute to the tolerization of cognate naive and Th1 effector CD4 cells, they are not essential, indicating the involvement of a non-DC tolerogenic APC population(s). Tolerogenic APCs, however, do not require the cooperation of CD4(+)CD25(+) regulatory T cells. Similarly, DC were required for maximal priming of naive CD4 cells to vaccinia viral-Ag, but priming could still occur in the absence of DC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17641018      PMCID: PMC2846358          DOI: 10.4049/jimmunol.179.3.1524

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  45 in total

1.  CD4 cell priming and tolerization are differentially programmed by APCs upon initial engagement.

Authors:  Amy D Higgins; Marianne A Mihalyo; Patrick W McGary; Adam J Adler
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

2.  In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens.

Authors:  Steffen Jung; Derya Unutmaz; Phillip Wong; Gen-Ichiro Sano; Kenia De los Santos; Tim Sparwasser; Shengji Wu; Sri Vuthoori; Kyung Ko; Fidel Zavala; Eric G Pamer; Dan R Littman; Richard A Lang
Journal:  Immunity       Date:  2002-08       Impact factor: 31.745

3.  Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells.

Authors:  Chandrashekhar Pasare; Ruslan Medzhitov
Journal:  Science       Date:  2003-01-16       Impact factor: 47.728

4.  Effector CD4 cells are tolerized upon exposure to parenchymal self-antigen.

Authors:  Amy D Higgins; Marianne A Mihalyo; Adam J Adler
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

5.  Effector CD4 cell tolerization is mediated through functional inactivation and involves preferential impairment of TNF-alpha and IFN-gamma expression potentials.

Authors:  Meixiao Long; Amy D Higgins; Marianne A Mihalyo; Adam J Adler
Journal:  Cell Immunol       Date:  2003-08       Impact factor: 4.868

6.  Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.

Authors:  R P Sutmuller; L M van Duivenvoorde; A van Elsas; T N Schumacher; M E Wildenberg; J P Allison; R E Toes; R Offringa; C J Melief
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

7.  Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo.

Authors:  D Hawiger; K Inaba; Y Dorsett; M Guo; K Mahnke; M Rivera; J V Ravetch; R M Steinman; M C Nussenzweig
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

8.  Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node.

Authors:  Clemens Scheinecker; Rebecca McHugh; Ethan M Shevach; Ronald N Germain
Journal:  J Exp Med       Date:  2002-10-21       Impact factor: 14.307

9.  The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens.

Authors:  Gabrielle T Belz; Georg M N Behrens; Chris M Smith; Jacques F A P Miller; Claerwen Jones; Kristina Lejon; C Garrison Fathman; Scott N Mueller; Ken Shortman; Francis R Carbone; William R Heath
Journal:  J Exp Med       Date:  2002-10-21       Impact factor: 14.307

10.  CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses.

Authors:  Susmit Suvas; Uday Kumaraguru; Christopher D Pack; Sujin Lee; Barry T Rouse
Journal:  J Exp Med       Date:  2003-09-15       Impact factor: 14.307

View more
  9 in total

Review 1.  The stromal and haematopoietic antigen-presenting cells that reside in secondary lymphoid organs.

Authors:  Shannon J Turley; Anne L Fletcher; Kutlu G Elpek
Journal:  Nat Rev Immunol       Date:  2010-11-19       Impact factor: 53.106

Review 2.  Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?

Authors:  Joseph M Ryan; Jeffrey S Wasser; Adam J Adler; Anthony T Vella
Journal:  Expert Opin Biol Ther       Date:  2016-02-25       Impact factor: 4.388

3.  Tolerance of activated pathogenic CD4+ T cells by transcriptional targeting of dendritic cells.

Authors:  B de Andrade Pereira; M Ackermann; S Chaudhary; R Vogel; B Vogt; C Dresch; C Fraefel
Journal:  Gene Ther       Date:  2015-03-05       Impact factor: 5.250

4.  Suppression of the immune response to FVIII in hemophilia A mice by transgene modified tolerogenic dendritic cells.

Authors:  Rui-Jun Su; Angela Epp; Junli Feng; Jackie Roy; Yvette Latchman; Xiaoping Wu; Doug Bolgiano; Neil C Josephson
Journal:  Mol Ther       Date:  2011-07-19       Impact factor: 11.454

5.  FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer.

Authors:  Stephanie K Watkins; Ziqiang Zhu; Elena Riboldi; Kim A Shafer-Weaver; Katherine E R Stagliano; Martha M Sklavos; Stefan Ambs; Hideo Yagita; Arthur A Hurwitz
Journal:  J Clin Invest       Date:  2011-03-23       Impact factor: 14.808

6.  Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells.

Authors:  Derese Getnet; Charles H Maris; Edward L Hipkiss; Joseph F Grosso; Timothy J Harris; Hung-Rong Yen; Tullia C Bruno; Satoshi Wada; Adam Adler; Robert W Georgantas; Chunfa Jie; Monica V Goldberg; Drew M Pardoll; Charles G Drake
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

7.  The E3 ubiquitin ligase Cbl-b regulates expansion but not functional activity of self-reactive CD4 T cells.

Authors:  Marie-Clare St Rose; Harry Z Qui; Suman Bandyopadhyay; Marianne A Mihalyo; Adam T Hagymasi; Robert B Clark; Adam J Adler
Journal:  J Immunol       Date:  2009-10-15       Impact factor: 5.422

8.  CD134/CD137 dual costimulation-elicited IFN-γ maximizes effector T-cell function but limits Treg expansion.

Authors:  Marie-Clare St Rose; Roslyn A Taylor; Suman Bandyopadhyay; Harry Z Qui; Adam T Hagymasi; Anthony T Vella; Adam J Adler
Journal:  Immunol Cell Biol       Date:  2013-01-08       Impact factor: 5.126

9.  Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation.

Authors:  Adam J Adler; Anthony T Vella
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.